The use of antiretroviral drugs for treating and preventing HIV infection. 2016 [cited 2017 Sep 13]. Available at: http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1.
The human immunodeficiency virus and acquired immune deficiency syndrome (prevention and control) act, 2017. [cited 2017 Sep 22]. Available at: http://naco.gov.in/sites/default/files/HIV AIDS Act.pdf.
Safrin S. Antiviral agents. In: Katzung BG, editor. Basic and Clinical Pharmacology. New Delhi: McGraw-Hill Education, 2015:835–65.Google Scholar
Brennan AT, Shearer K, Maskew M, Long L, Sanne I, Fox MP. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health 2014;19:490–8.CrossrefWeb of SciencePubMedGoogle Scholar
Agu K, Ochei U, Oparah A, Onoh O. Treatment outcomes in patients receiving combination antiretroviral therapy in central hospital, Benin City, Nigeria. Trop J Pharm Res 2010;9:1–10.Google Scholar
HIV treatment and care. 2017 [cited 2017 Sep 13]. Available at: http://apps.who.int/iris/bitstream/10665/255891/1/WHO-HIV-2017.22-eng.pdf?ua=1.
Manohar HD, Shenoy S, Varma M, Kamath A, Malalur C, Bairy KL, et al. Antiretroviral therapy outcome in human immuno-deficiency virus infected patients in a tertiary care hospital. Int J Basic Clin Pharmacol 2016;5:616–22.Google Scholar
Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, Nelson LJ, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique’s rapidly expanding antiretroviral therapy program. PLoS One 2011;6:e18453.CrossrefPubMedWeb of ScienceGoogle Scholar
Kipp W, Konde-Lule J, Saunders LD, Alibhai A, Houston S, Rubaale T, et al. Antiretroviral treatment for HIV in rural Uganda: two-year treatment outcomes of a prospective health centre/community-based and hospital-based cohort. PLoS One 2012;7:e40902.CrossrefWeb of ScienceGoogle Scholar
Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S, Mothi SN, Solomon S. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr 2008;55:155–9.PubMedWeb of ScienceGoogle Scholar
Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, Bulterys M, et al. Five-year outcomes of the China national free antiretroviral treatment program. Ann Intern Med 2009;151:241–51.CrossrefPubMedWeb of ScienceGoogle Scholar
Shah B, Walshe L, Saple DG, Mehta SH, Ramnani JP, Kharkar RD, et al. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis 2007;44:1235–44.CrossrefPubMedWeb of ScienceGoogle Scholar
Kumarasamy N, Safren SA, Raminani SR, Pickard R, James R, Krishnan AS, et al. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS 2005;19:526–37.CrossrefPubMedGoogle Scholar
Soriano V, Dona C, Rodríguez-Rosado R, Barreiro P, Lahoz JG. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. Aids 2000;14:383–6.PubMedCrossrefGoogle Scholar
Bachani D, Garg R, Rewari BB, Hegg L, Rajasekaran S, Deshpande A, et al. Two-year treatment outcomes of patients enrolled in India’s national first-line antiretroviral therapy programme. Natl Med J India 2010;23:7–12.PubMedGoogle Scholar
Huang P, Tan J, Ma W, Zheng H, Lu Y, Wang N, et al. Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014. BMJ Open 2015;5:e007508.Web of ScienceCrossrefPubMedGoogle Scholar
Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One 2013;8:e64459.CrossrefGoogle Scholar
Mosha F, Muchunguzi V, Matee M, Sangeda RZ, Vercauteren J, Nsubuga P, et al. Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. BMC Public Health 2013;13:38.Web of ScienceCrossrefGoogle Scholar
Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010;50:1387–96.PubMedWeb of ScienceGoogle Scholar
Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J 2004;170:229–38.Google Scholar
Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW, Adult/Adolescent Spectrum of Disease Group. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998;91:301–8.PubMedGoogle Scholar
Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis 2010;50:416–25.PubMedCrossrefWeb of ScienceGoogle Scholar
Evans D, Menezes C, Mahomed K, Macdonald P, Untiedt S, Levin L, et al. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses 2013;29:892–900.PubMedWeb of ScienceCrossrefGoogle Scholar
Kowalska JD, Kubicka J, Siwak E, Pulik P, Firląg-Burkacka E, Horban A. Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients. AIDS Res Ther 2016;13:2.CrossrefWeb of SciencePubMedGoogle Scholar
Tsuchiya N, Pathipvanich P, Wichukchinda N, Rojanawiwat A, Auwanit W, Ariyoshi K, et al. Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study. BMC Infect Dis 2014;14:565.PubMedWeb of ScienceCrossrefGoogle Scholar
Kušić J, Mladenović M, Dimitrijević B, Aleksić B, Zec S, Jevtović D, et al. Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia. J Virus Erad 2016;2:32.PubMedGoogle Scholar
About the article
Published Online: 2019-03-22
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.